1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Ltd.

346.20
INR
+3.95
(+1.15%)
6.74EPS
29.61P/E
17.77BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
235.6
161.23
159.47
168.31
169.19
161.81
157.62
150.85
175.8
204.33
289.26
83.51
74.83
80.13
Basic EPS, GAAP
-29.79
-29.14
-14.33
-9.2
4.88
6.19
-4.28
-0.53
-0.36
8.06
91.18
37.24
5.16
6.91
Free Cash Flow per Basic Share
8.44
14.44
10.71
14.91
11.52
-17.07
23.06
22.09
22.32
30.78
-44
-13.84
-18.64
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
177.05
145.14
126.31
118.76
121.26
123.57
108.42
102.14
101.71
115.41
137.44
193.5
159.38
- -
Tangible Book Value per Share
111.77
84.03
70.52
72.58
92.16
107.56
101.47
100.55
101.54
115.41
135.66
191.74
156.22
- -
Basic Weighted Avg Shares
41
41
41
43
45
47
49
59
59
59
59
67
84
83
Sales/Revenue/Turnover
9,651
6,605
6,532
7,162
7,625
7,566
7,796
8,913
10,387
12,073
17,091
5,617
6,259
6,647
Operating Margin (%)
0.21
3.85
5.11
4.82
8.11
5.89
9.38
12.45
8.9
15.04
14.19
-7.41
-0.77
4.23
Depreciation Expense
658
843
847
883
866
1,040
901
873
1,310
574
804
245
306
315
Net Income, GAAP
-1,220
-1,194
-587
-391
220
289
-212
-31
-21
476
5,388
2,505
431
573
Effective Tax Rate (%)
- -
- -
- -
- -
38.93
41.73
- -
117.48
117.15
44.72
9.86
2.82
15.23
19.67
Profit Margin (%)
-12.64
-18.07
-8.98
-5.46
2.88
3.83
-2.72
-0.35
-0.21
3.94
31.52
44.59
6.89
8.62
Working Capital
3,589
870
-1,454
-1,733
-976
4,801
5,400
6,297
7,409
7,934
5,265
6,448
7,195
- -
LT Debt
9,644
8,161
6,842
5,920
5,205
9,656
8,913
8,846
8,483
7,531
1,990
259
123
- -
Total Equity
7,252
5,945
5,174
5,313
5,490
5,878
6,406
6,034
6,009
6,819
8,121
11,730
13,840
- -
Return on Invested Capital (%)
- -
- -
- -
- -
2.32
4.76
- -
-1.18
-0.85
5.44
44.66
16.7
-1.08
- -
Return on Capital (%)
- -
- -
- -
- -
2.44
5
- -
-1.19
-1.13
6.16
48.73
22.54
3.32
- -
Return on Common Equity (%)
-15.46
-18.09
-10.56
-7.46
4.07
5.09
-3.45
-0.51
-0.36
7.42
72.12
25.24
3.37
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
56
- -
LT Borrowings
- -
121
- -
LT Finance Leases
- -
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
82
87
87
Market Capitalization
7,197
11,428
17,767

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,768
- -
Cash, Cash Equivalents & STI
- -
4,418
- -
Accounts Receivable, Net
- -
1,985
- -
Inventories
- -
1,479
- -
Total Current Liabilities
- -
2,573
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
56
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.08%
18.92%
17.99%
Free Cash Flow
-65.66%
-40.16%
67.45%
Net Income, GAAP
-186.7%
-290.19%
-82.78%
Sales/Revenue/Turnover
5.13%
3.73%
11.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
332
1,483
1,288
1,424
5,617
2026
1,583
1,526
1,509
1,698
6,259
2027
1,915
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.16
0.67
-0.82
33.04
37.24
2026
1.28
1
1.17
1.81
5.16
2027
2.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Navrattan R. Munjal
Full Time Employees
1,388
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Shivalik Enclave Manimajra CD India 160101
IPO Date
Mar 15, 2002
Website
indswiftlabs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ind-Swift Laboratories Limited manufactures active pharmaceutical ingredients, intermediates and formulations through group collaborations for global regulatory markets including the US, Europe and emerging regions. The company, founded in 1995 and headquartered in Chandigarh, India, specializes in APIs across therapeutic areas such as cardiovascular health including Atorvastatin Calcium and Ranolazine; antihistaminic; antidiabetic; antipsychotic including Aripiprazole; antimigraine; Parkinson's disease including Ropinirole HCl; antineoplastic including Letrozole and Anastrozole; ADHD symptoms; analgesics; alcohol abstinence; bone resorption inhibitors including Risedronate Sodium; and holds global leadership in macrolide antibiotics including Clarithromycin and its derivatives; it also provides contract research and manufacturing services with a 40,000 sq ft R&D center in Mohali, Punjab that has developed over 50 APIs and filed multiple DMFs. Facilities feature approvals from USFDA, EDQM, ANVISA, KFDA and others, supporting exports to regulated and row markets via six modern manufacturing sites. Recent developments include the sale of its API and CRAMS businesses to PI Industries via slump sale effective March 18, 2024; merger with Ind Swift Limited approved by NCLT and effective August 8, 2025 with appointed date March 31, 2024, involving allotment of preference shares and conversion of equity warrants; approval at June 2024 EGM for business expansion and investments up to INR 1,500 million in wholly owned subsidiaries by December 2027 including strategic greenfield and brownfield opportunities in India and abroad, plus INR 500 million in subsidiary loans or equity by December 2026; and strategic asset sales such as plant machinery to ANG Lifesciences for Rs 38.40 crores contributing to robust FY2025 profits of Rs 256 crores standalone.